genes can alter the enzyme activity of IM and may affect its response. In this study, the impact of two single-nucleotide polymorphisms (SNPs),
CYP3A5*3
(6986A[G) and CYP3A4*18
(878T[C), on IM treatment response in CML patients (n = 270; 139 IM resistant and 131 IM good responders) was investigated.
Methods: Genotyping of CYP3A4*18 and CYP3A5*3 was performed using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) technique.
The association between allelic variants and treatment response was assessed by means of odds ratio (OR) with 95% confidence intervals calculated by logistic regression. reported by our group [2] . Drug-metabolizing enzymes (DME) are involved in deactivating xenobiotics as well as biotransformation of drugs, and polymorphisms in DME coding genes have been reported to alter the activity of the enzymes for some substrates [3] .
Therefore, genetic variation in drug metabolism can lead to therapeutic failures, adverse drug effects or even fatal drug intoxications [4] .
Xenobiotic metabolism is mainly conducted by three main cytochrome P450 (CYP) gene families: CYP1, CYP2 and CYP3, with the most highly expressed subfamily being the CYP3A. Genetic variation in CYP3A activity may influence the rate of metabolism and elimination of CYP3A substrates including IM.
The metabolism of IM is mainly mediated by CYP3A4 and CYP3A5 [5] . It is suggested that CYP3A4 and CYP3A5 are important genetic contributors to inter-individual differences in CYP3A-dependent drug metabolism. A polymorphism of CYP3A4*18, located at exon 10, had been reported as the common allelic variation of CYP3A4. This polymorphism involves nucleotide change from tyrosine (T) to cytosine (C) transition at position 878
and results in an amino acid change from leucine to proline at codon 293 (Leu293Pro) [6, 7] . CYP3A4*18 had been reported to be associated with high turnover of testosterone and chlorpyrifos when compared to the wild type [8] . CYP3A5*3 is another common allelic variation in CYP3A5. Polymorphism in CYP3A5*3 plays a crucial role in the pharmacokinetics of these CYP3A substrates. It is reasonable to assume that polymorphisms in the CYP3A5 gene could lead to interindividual variability, which has been observed in the pharmacokinetic changes seen with CYP3A
substrates [9] . This study was designed to investigate the frequency of single-nucleotide 
METHODS

Subjects and DNA Extraction
The study was approved by the Research and metaphases) [11] . Molecular response was best assessed according to the International Scale (IS) as the ratio of BCR-ABL1% on a log scale, where 10%, 1%, 0.1%, 0.01%, 0.0032% and 0.001% correspond to a decrease of 1, 2, 3, 4, 4.5 and 5 logs, respectively, below the standard baseline that was used in the IRIS study. A BCR-ABL1 expression of B0.1% corresponds to major molecular response (MMR) [10] . CML patients who achieved the above-mentioned response criteria were categorized as IM good responders and those who did not achieve the above response criteria within the specified time frame were categorized under the IM non-responders/resistant group.
Peripheral blood (3 ml) was collected after obtaining written informed consents from the subjects. Genomic DNA was extracted using a DNA extraction kit, QIAGEN QIAamp Ò DNA Blood Mini kit (QIAGEN, Hilden, Germany), according to the manufacturer's instructions. Genotyping was conducted at Human Genome Centre, Universiti Sains Malaysia.
Genotyping of CYP3A4*18 Polymorphisms
Genotyping of CYP3A4*18 was performed by using the polymerase chain reaction restriction Following PCR amplification, 4 ll of PCR products was digested by restriction enzyme 
RESULTS
Two hundred seventy (270) CML patients (139 IM resistant and 131 good responders) were successfully recruited. Table 1 shows the patients' characteristics. In the present study, the gender, age and CML stages did not show any influence on IM response (data not shown). In the PCR-RFLP analyses, the restriction enzymes were successfully cut at the correct regions for CYP3A4*18 and CYP3A5*3 ( Fig. 1) , which was confirmed by the sequencing result (Fig. 2) To establish the risk association of CYP3A4*18 and CYP3A5*3 polymorphisms with IM response, a binary logistic regression was performed (Table 3) . For CYP3A4*18, there was no significant association between the polymorphism and the risk of acquiring resistance toward IM. However, for CYP3A5*3 polymorphisms, both heterozygous (AG) and homozygous variants (GG) posed significantly (p\0.001) lower risk for acquiring resistance toward IM. We determined that these two SNPs,
rs28371759
(CYP3A4*18) and rs776746 (CYP3A5*3), are in low linkage disequilibrium (r 2 = 0) probably as a result of recombination occuring between the two markers (Fig. 3) . 
DISCUSSION
To the best of our knowledge, this is the first study reporting the impact of polymorphism of CYP3A4*18 and CYP3A5*3 in IM treatment response in Malaysian CML patients. For CYP3A4*18, no homozygous variant (*18/*18) was detected among both IM resistant and good responders. This is similar to the findings among the Malaysian population reported by Ruzilawati et al. [13] who did not detect any homozygous variant, indicating that this genotype, which contributes to slower metabolism of most xenobiotics, is rather rare in the Asian population.
CYP3A4*18 was detected at a frequency of 1.7% in a healthy Korean population [14] , 2% in a healthy Chinese population [8] , 1.3% in a healthy Japanese population [15] and 2.07% among Malaysian diabetics [13] . The allelic frequencies of CYP3A4*18 among CML patients in Malaysia was almost double (4.44%) that reported among
Malaysian diabetics indicating that the polymorphism may play a role in contributing to the disease. However, in another study among the Indian population to associate CYP3A4*18 variant alleles with IM levels, although high inter-patient variability of IM levels were seen, no CYP3A4*18 variants were detected to establish any significant correlation [16] .
For CYP3A5, the mutant allele CYP3A5*3 has been reported to contribute to the variable expression in the human liver. This mutation [20] and also among Indian CML patients [21] . However, Takahashi et al. [22] on Japanese patients and Angelini et al. [23] on Caucasian patients reported no significant association of the CYP3A5*3 polymorphism with IM response. Our findings showed that there is a significant association of CYP3A5*3 polymorphism with IM response but with lower risk for development of resistance. Moreover, we also found that the CYP3A5*1 genotype was higher in the IM-resistant group compared with the IM good-response group. Hence, it is reasonable to suggest that carriers of CYP3A5*3 tend to have a protective effect against acquiring resistance toward IM therapy.
CYP3A5 contributes substantially to the total metabolic clearance of many CYP3A substrates.
Since individuals with at least one CYP3A5*1 allele polymorphism express high amounts of CYP3A5, it is reasonable to predict that individuals with the highest clearance and lowest oral bioavailability of CYP3A substrates will be heterozygous or homozygous for CYP3A5*1. Hence, carriers of heterozygous and homozygous CYP3A5*1 genotypes may be more likely to encounter a lack of efficacy from a standard dose of active parent drug. Likewise, the homozygous CYP3A5*3 genotype can lead to a decrease in enzyme activity resulting in lowest clearance and high bioavailability of the 
